Thus, blocking TSLP with tezepelumab may impact numbers of these cell types in the bronchial submucosa of patients with moderate-to-severe asthma, via effects on cellular activation, development and migration to inflamed tissues, suggesting potential efficacy in a range of patients, including those with non-eosinophilic phenotypes. This evidence concerns the gene TSLP and asthma.